Fulgent Genetics, Inc. (FLGT) Q1 FY26 Earnings Call

Customer attrition pressures Q1, but acquisitions and clinical progress underpin reiterated full-year revenue guidance.

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Length39 minutes
EPS$-0.64
EPS consensus$-0.53
Revenue$71.1M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY26 · Q4 FY25

All FLGT earnings · Back to FLGT overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.